Description
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
This trial is available at multiple Sutter Locations. Please contact one of the following about Study SWOG S1418/BR006
San Francisco: Clinicalresearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Isabel Rodrigues-Fong Rodrigi@sutterhealth.org and Kirsten Babski babskik@sutterhealth.org
Modesto: Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo: Stephanie Casal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org
Santa Rosa: Patricia Grinnell GrinneP@sutterhealth.org and Mohammad Naseem NaseemMK@sutterhealth.org
View study details on ClinicalTrials.gov
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
February 01, 2019
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: External PI, Principal Investigator, Xiaowei (Sherry) Yan, PhD, MS
Impact of COVID-19 on Cancer Care Management
Investigators: Monique de Bruin, M.D., MPH, Su-Ying Liang, Ph.D.